Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib
Patient Information
The clinical data presented involves a cohort of 48 patients diagnosed with relapsed or refractory (R/R) acute myeloid leukemia (AML). These patients were specifically selected based on the presence of high-risk molecular features, specifically rearrangements in the lysine methyltransferase 2A (KMT2A) gene or mutations in the nucleophosmin 1 (NPM1) gene. These genetic alterations are known to render the leukemia dependent on the menin-KMT2A interaction for the maintenance of an undifferentiated, proliferative state. The patients in this study had previously failed standard-of-care therapies, including intensive chemotherapy and/or targeted agents, leading to their enrollment in clinical trials for revumenib, a potent and selective menin inhibitor.
Diagnosis
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.